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Abstract
Purpose: Uterine sarcomas are rare and heterogeneous tumors
characterized by an aggressive clinical behavior. Their high rates of
recurrence and mortality point to the urgent need for novel
targeted therapies and alternative treatment strategies. However,
nomolecular prognostic or predictive biomarkers are available so
far to guide choice and modality of treatment.
Experimental Design: We investigated the expression of several
druggable targets (phospho-S6S240 ribosomal protein, PTEN,
PDGFR-a, ERBB2, and EGFR) in a large cohort of human uterine
sarcoma samples (288), including leiomyosarcomas, low-grade and
high-grade endometrial stromal sarcomas, undifferentiated uterine
sarcomas, and adenosarcomas, together with 15 smooth muscle
tumors of uncertain malignant potential (STUMP), 52 benign
uterine stromal tumors, and41normal uterine tissues. Thepotential
therapeutic value of the most promising target, p-S6S240, was tested
in patient-derived xenograft (PDX) leiomyosarcoma models.
Results: In uterine sarcomas and STUMPs, S6S240 phos-
phorylation (reﬂecting mTOR pathway activation) was asso-
ciated with higher grade (P ¼ 0.001) and recurrence (P ¼
0.019), as shown by logistic regression. In addition, p-S6S240
correlated with shorter progression-free survival (P ¼ 0.034).
Treatment with a dual PI3K/mTOR inhibitor signiﬁcantly
reduced tumor growth in 4 of 5 leiomyosarcoma PDX models
(with tumor shrinkage in 2 models). Remarkably, the 4
responding models showed basal p-S6S240 expression, where-
as the nonresponding model was scored as negative, suggest-
ing a role for p-S6S240 in response prediction to PI3K/mTOR
inhibition.
Conclusions:Dual PI3K/mTOR inhibition represents an effec-
tive therapeutic strategy in uterine leiomyosarcoma, and p-S6S240
expression is a potential predictive biomarker for response to
treatment. Clin Cancer Res; 23(5); 1274–85. 2017 AACR.
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Introduction
Uterine sarcoma is the general term referring to aheterogeneous
group of rare neoplasms with diverse histologic features, that
together account for 3,4% of all uterine corpus malignancies (1).
Although rare, they entail substantial morbidity and mortality,
with frequent recurrences and distant metastases, even after
hysterectomy (2). Leiomyosarcoma is the most frequently diag-
nosed and a very aggressive subtype, accounting for 60% of all
uterine sarcomas (1). Low-grade endometrial stromal sarcomas
(LGESS) account for 20% of uterine sarcomas, and they usually
follow a less aggressive disease course compared with leiomyo-
sarcoma, with a more indolent growth and delayed recurrences
(2). The remaining 20% of uterine sarcomas comprise high-grade
ESS (HGESS), undifferentiated uterine sarcoma (UUS), and ade-
nosarcomas. Smooth muscle tumors of uncertain malignant
potential (STUMP) also arise from the myometrium, and repre-
sent a very rare entity that cannot be diagnosed as benign or
malignant (3). Uterine sarcoma subtypes with HG histology are
generally the most aggressive and are associated with poor prog-
nosis. Adjuvant treatment is decided on the basis of the histologic
subtype, but in general is scarce and of limited beneﬁt, under-
lining the urgent need for new treatment options (2, 4).
During the past decade, our knowledge on the molecular
aspects of sarcomas has expanded thanks to the advent of next-
generation sequencing methods, which allowed biomarker
identiﬁcation and categorization into molecular and prognostic
subgroups (5, 6). However, although efforts have been taken
to identify therapeutic targets in sarcomas of the uterus, little
consensus has been attained so far on their expression prevalence,
mainly because of the limited sized sample sets available, varia-
tions in detection protocols, and different cutoffs for positivity. In
this study, we present the results of an immunohistochemical
screening of relevant targets performed on one of the largest
human uterine sarcoma sample sets published so far. Through
collaboration within the European Network of Individualized
Treatment in Endometrial Cancer (ENITEC), we collected more
than 300 human uterine sarcoma samples and corresponding
clinical data, being able to perform disease course analysis and
investigate correlations between potential targets and clinical
parameters. For targets' analysis, we selected phosphorylated S6
ribosomal protein (p-S6S240), the tumor suppressor and PI3K
pathway inhibitor PTEN, platelet-derived growth factor receptor-a
(PDGFR-a), erb-b2 receptor tyrosine kinase 2 (ERBB2/HER-2),
and EGFR. Phosphorylated S6 is an important downstreamplayer
in the mTOR pathway, and PTEN inhibits the PI3K pathway
upstream. PI3K/mTOR signaling has been implicated in leiomyo-
sarcoma, conﬁrmed by in vitro and in vivo studies (7, 8). PDGFR,
ERBB2, and EGFR all have proven to be valuable targets in other
cancer types. PDGFR, for example, is blocked by imatinib in
gastrointestinal stromal tumors and dermatoﬁbrosarcoma pro-
tuberans (9),whereas ERBB2overexpression is tackled by the anti-
ERBB2 antibodies trastuzumab and pertuzumab in breast cancer
(10). Finally, EGFR is targeted by antibodies such as panitumu-
mab in head and neck and colon cancer, and by tyrosine kinase
inhibitors geﬁtinib and erlotinib in non–small cell lung cancer
(11). To validate the results of such screening, we preclinically
tested themost promising target in an in vivo context, using uterine
sarcoma patient-derived xenograft (PDX) models. Of note, being
established by implanting freshly isolated tumor fragments into
immunocompromised mice, PDXs have proven high histologic
andmolecular similarity to the original tumor (12), together with
high predictive value in terms of response to therapy (13).
Materials and Methods
Patient samples
After obtaining approval from the Medical Ethics Committee
UZ/KU Leuven and Ethics Boards in collaborating centers, 303
archived formalin-ﬁxed, parafﬁn-embedded sarcoma samples (6
of which are recurrences of included primary tumors), 52 benign
uterine tumors, and 41 normal tissues were collected from 19
European hospitals, 13 of which are associated to ENITEC. A total
of 307unique tumor samples (malignant andbenign), alongwith
clinical data, were collected through ENITEC, with the following
collaborating centers: UZ Leuven, Belgium (n¼ 100), Vall d'Heb-
ron University Hospital, Barcelona, Spain (n ¼ 37), MUMC
Maastricht, Maastricht, the Netherlands (n ¼ 35), Charles Uni-
versity in Prague—1st Faculty of Medicine, Prague, Czech Repub-
lic (n ¼ 23), Turku University Hospital, Turku, Finland (n ¼ 23),
University Hospital Graz, Graz, Austria (n ¼ 23), Haukeland
University Hospital, Bergen, Norway (n ¼ 22), Provincial
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Hospitals in Gdynia - Oncology Center, Gdynia, Poland (n¼ 11),
Radboud UMC, Nijmegen, the Netherlands (n ¼ 7), University
Hospital Bonn, Bonn, Germany (n ¼ 7), UMC Utrecht, Utrecht,
the Netherlands (n ¼ 7), University Hospitals K€oln, K€oln, Ger-
many (n ¼ 6), and Karolinska University Hospitals, Stockholm,
Sweden (n ¼ 6). Remaining tumor samples were contributed by
MST Enschede (Enschede, the Netherlands), ZGT Almelo and
Hengelo and SKBWinterswijk, the Netherlands (n¼ 26), St. Jean,
Ste. Anna-St. Remi and St. Etienne, Brussels, Belgium (n ¼ 11),
Yperman, Ieper, Belgium (n¼ 2), AZ Turnhout, Belgium (n¼ 1),
Mariaziekenhuis, Overpelt, Belgium (n ¼ 1), and Imelda Hospi-
tal, Bonheiden, Belgium (n ¼ 1). The sample set included 157
leiomyosarcomas (4 recurrent matching to primary leiomyosar-
coma), 68 LGESSs, 26 UUSs, 15 HGESSs (2 recurrent matching to
primary LGESS), 17 adenosarcomas, 15 STUMPs, 5 HG uterine
sarcomas, not otherwise speciﬁed (HG uSAR NOS), 44 leiomyo-
mas, 8 endometrial stromal nodules (ESN), 23 healthy myome-
trial specimens, and 18 healthy endometrial samples. Of all
collected tissue blocks, 6.5% was obtained from surgeries before
2000, 62.5% was obtained between 2000 and 2010, and 31%
dated from 2010 or later. Patient follow-up ranged from 1month
to 30 years. In addition to the external classiﬁcation of tumors,
carried out in the center of origin by the local pathologist, all cases
were reviewed and reclassiﬁed in a blinded manner by the
dedicated central pathologist P. Moerman, uterine tumors expert,
according to the WHO 2014 classiﬁcation (14). Cases with
discordant diagnoses were excluded, and only cases where con-
cordance was reached by the two independent pathologists were
included for the screening. For clinical data collection, the Inter-
national Federation of Gynecologic Oncology 2009 system was
applied for staging of all samples (see Supplementary Table S1 for
clinical data and treatment modalities). HG cases were the fol-
lowing: all leiomyosarcoma, HGESS and UUS, HG uSAR NOS,
and adenosarcoma with sarcomatous overgrowth. LG cases were
all LGESS and LG adenosarcoma.
Immunohistochemical stainings
Parafﬁn slides (4 mm) were heated for 3 to 4 hours at 55C,
deparafﬁnized in toluol, and rinsed in ethanol. Tissues were
blocked for endogenous peroxidases by 30-minute incubation
in 0.5% H2O2 (107209, Merck Millipore) in methanol. After
washing in TBS, epitopes were retrieved as displayed in Supple-
mentary Table S2, which summarizes details of the IHCmethods.
Tissues were cooled down slowly in TBS, except after enzymatic
retrieval of EGFR, which was stopped by 5-minute incubation in
cold (4C) TBS. Upon extensive washing, tissues were blocked
with 1%milk powder, 2%BSA (A4503, Sigma-Aldrich), and0.1%
Tween-80 (822187, Merck Millipore) in TBS before antibody
incubation. Blocking solutions were removed and tissues were
incubated with antibody solutions in TBS (Supplementary Table
S2). The following primary antibodies were used: anti-phospho-
S6S240 (M7300, Dako), anti-PTEN (clone 6H2.1, M3627, Dako),
anti-PDGFR-a (C-20, sc-338, Santa Cruz Biotechnology), anti-
ERBB2 (A0485, Dako), and anti-EGFR (clone 31G7, 280005,
Zymed). Tissues were washed, blocked for 15 minutes (except
for PTEN staining), and incubated with secondary antibodies or,
for PTEN, with EnVision-HRP (K4001, Dako). After washing,
slides for EGFR and phospho-S6S240 stainings were incubated
with streptavidin–HRP (P0397, Dako) for 30 minutes and
washed again. All antibodies were visualized by 10-minute incu-
bation in 3,30-diaminobenzidine (DAB, D5905, Sigma) þ
0.015% H2O2 (107209, Merck Millipore) in the dark. Nuclei
were stained with Mayer's hematoxylin, and tissues were dehy-
drated in propanol, dipped in xylene, and mounted. Positive
controls consisted of PDGFR-expressing ovarian carcinoma,
PTEN-expressing normal endometrium, ERBB2-expressing breast
carcinoma, EGFR-expressing tumor (grown in nude mice) from
human HEC cells and S6-expressing endometrial carcinoma with
S6 phosphorylation, conﬁrmed by Western blot analysis. To
ensure no staining was caused by a speciﬁc binding of second-
ary/tertiary molecules, control slides without addition of primary
antibody were used.
Evaluation and scoring of immunohistochemical stainings
All stainings were evaluated semiquantitatively, using a scoring
system (Supplementary Table S3) that takes into account both the
staining intensity (0 ¼ absent, 1 ¼ weak, 2 ¼moderate, and 3 ¼
strong) and the percentage of stained cells (0 ¼ absent, 1 ¼ less
than 1%, 2 ¼ 1%–10%, 3 ¼ 11%–33%, 4 ¼ 34%–66%, and 5 ¼
67%–100%; ref. 15). Both scores were added to obtain a maxi-
mum score of 8. Stainings were evaluated only in the cellular
component where expression was expected. Tissues were consid-
ered positive at a cut-off score of 6, corresponding to strong
positivity in11% of cells, moderate positivity in34% of cells,
or weak staining in 67% of cells. This cutoff was deemed
clinically relevant for therapeutic applications, as a targeted ther-
apy would most likely be effective when a sufﬁcient number of
cells express the target. For ERBB2, this coincides with the gen-
erally applied scoring system approved by the FDA (16). Tissues
were evaluated by the observer (T. Cuppens) and in randomly
selected cases (25%) additionally by a second observer (A. Coose-
mans). For these speciﬁc cases, a concordance of >90% was
reached between scorings by the two independent researchers.
Photographs of representative cases were taken using the Axios-
kop microscope (MRc5, Zeiss) and the ZEN 2.0 software.
Establishment and validation of PDX models
Animal experiments were approved by the Animal Ethics
Committee of KU Leuven (Leuven, Belgium). Mouse xeno-
graft models were established in collaboration with the Trace
Platform (UZ/KU Leuven). Small fragments of tumor tissue
(3  3  3 mm), obtained during necessary surgery or biopsy
upon informed consent, were implanted interscapularly in
female NMRI nude mice of minimum 6 weeks old (Taconic)
and expanded in several generations.
Treatment of PDX models
Mice were randomized according to tumor volume (when
tumor volumes reached 200–250 mm3) and treated for 19 to
22days (5–9mice/group for BEZ235- andplacebo-treatedgroups,
3–7 mice for trabectedin-treated groups). Some mice in the
trabectedin groups were excluded due to signs of toxicity around
the tail vein. BEZ235 (also known as dactolisib; Novartis, through
Selleckchem, S1009) was prepared in 10% N-methyl-2-pyrroli-
done (sc-237581, Santa Cruz Biotechnology)/90% polyethylene
glycol (90878, Sigma) and administered orally, daily, in a dose of
40 mg/kg. Placebo-treated mice received the same volume of
vehicle as the BEZ235-treated group. Trabectedin (Yondelis) was
acquired from the UZ Leuven Hospital Pharmacy, aliquoted in
DMSO (102952, Merck Millipore), and diluted in saline. It was
administered intravenously (0.15 mg/kg; tail vein), once weekly.
Tumor volumes were measured with a caliper twice weekly
Cuppens et al.
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(calculated using the following formula: length width  depth
 p/6), and mice body weights were monitored. Treatment was
discontinued after 3weeks orwhen the tumor reacheda volumeof
2,000 mm3. After sacriﬁce, all tumors were stained and scored for
p-S6S240 level as before. Signiﬁcant weight loss was deﬁned as a
loss of 15% of the body weight recorded at the beginning of the
treatment.
Statistical analyses
IBM SPSS Statistics 20 was used for all statistical analyses
except for the in vivo treatment experiments. Age and tumor size
were considered continuous variables, whereas all other vari-
ables were categorical. The c2 test was used to compare staining
results (portion of positive samples) between histologic sub-
groups. To determine potential associations between stainings
and clinical variables (e.g., stage, age, tumor size) for primary
versus recurrent tumors and LG versus HG histologies, univar-
iate analyses were ﬁrst carried out using c2 tests for categorical
variables. Next, logistic regression was performed including
only one variable for continuous and categorical variables, to
permit direct comparison with multivariate logistic regression
analysis, including all variables that showed a signiﬁcant cor-
relation in univariate analysis. Univariate survival analyses
were carried out using the Kaplan–Meier method/log-rank test.
In the in vivo treatment experiments, tumor volumes of different
treatment groups were compared over time using two-way
repeated measures ANOVA in GraphPad.
Results
HG uterine sarcomas are characterized by aggressive clinical
behavior and poor prognosis
We collected and analyzed the following patient samples:
leiomyosarcoma (n ¼ 153), LGESS (n ¼ 68), UUS (n ¼ 26),
HGESS (n ¼ 13), STUMP (n ¼ 15), adenosarcoma (n ¼ 17), and
HG uSAR NOS (n ¼ 5), which could not be categorized in any
conventional tumor group. Leiomyosarcoma, HGESS, UUS, and
HG uSAR NOS are HG tumors. Of 17 adenosarcoma patients, 4
were diagnosed with an HG variant (with sarcomatous over-
growth). The remaining adenosarcoma were considered LG, as
well as the LGESS. No grade was assigned to STUMP cases. The
most important clinical data summarized per histologic subtype
are shown in Supplementary Table S1. Information on disease-
speciﬁc survival (DSS) and progression-free survival (PFS) was
available for 242 and 210 patients, respectively. First, we pooled
all patients with HG and LG tumors and compared their survival,
conﬁrming that HG tumors are clinically more aggressive (Sup-
plementary Fig. S1A and S1B, both P< 0.001). For LGpatients, the
5-year DSS and PFS rates were 86% and 64%, respectively,
whereas for HG patients, after 5 years only 33% were alive and
18% showed no progression. Next, we determined survival rates
for all separate subtypes (Supplementary Fig. S1C and S1D). The
5-year DSS rate was 0% to 22% in UUS patients, around 30% in
HGESS patients, and 35% in leiomyosarcoma patients, contrast-
ing with 85% in LGESS patients. Concurrently, the 5-year PFS rate
was 0% to 10% in UUS patients, 0% to 29% in HGESS patients,
18% in leiomyosarcoma patients, and 63% in LGESS patients. Of
note, patients diagnosed with STUMP had a signiﬁcantly better
PFS compared with patients diagnosed with leiomyosarcoma
(median PFS ¼ 41 months in STUMP and 17 months in leio-
myosarcoma, P¼ 0.023), although the difference in DSS was not
signiﬁcant (median DSS ¼ 52 months in STUMP and 35 months
in leiomyosarcoma, P¼ 0.086), probably due to the low number
of STUMP patients. For adenosarcoma patients, the 5-year sur-
vival estimation was not feasible due to the smaller sample set,
with fewer events. The 3 HG adenosarcoma patients with avail-
able follow-up data died of disease within 26months (100%). Of
the patients with LG adenosarcoma, only 1 of 11 (9%) patients
died of disease (after 25months), and the follow-up time of other
patients was between 19 and 119 months.
Overall, patient subgroups with HG tumors are characterized
by a substantially worse prognosis, and the largest subgroup of
uterine sarcoma presented in our study, as in the general popu-
lation, is leiomyosarcoma.
The PI3K/mTOR pathway and PDGFR-a are potential targets in
different uterine sarcoma subtypes
On the basis of available literature data and therapeutic poten-
tial (i.e., for which therapeutic agents are available and active in
other cancer types), we investigated in our cohort of human
uterine sarcoma samples the expression of the following drug-
gable molecular targets: phospho-S6S240, PTEN, PDGFR-a,
ERBB2, and EGFR. Their expression levels were determined in a
total of 396 samples, including malignant tumors (leiomyosar-
coma, LGESS, HGESS, UUS, adenosarcoma, and HG uSARNOS),
tumors of uncertain malignancy (STUMP), benign tumors (leio-
myoma and ESN), and normal myometrium and endometrium.
Expression data for the ﬁve selected proteins are summarized
in Table 1, per histologic subgroup, and for pooled HG and LG
samples. Representative images for the stainings and a detailed
description of the adopted scoring system are shown in Supple-
mentary Fig. S2 and Supplementary Table S3, respectively. Tissues
were consideredpositive at a score of 6orhigher, corresponding to
weak staining in 67% of cells, moderate staining in 34% of
cells, or strong staining in 10% of cells. Considering all uterine
sarcomas and STUMP cases together, p-S6S240 was scored positive
in 26% of samples. Loss of PTEN expression was seen in 34% of
cases, with up to 50% loss in UUS samples. The most frequently
expressed protein was PDGFR-a (82%), while ERBB2 and EGFR
were detected in 5% and 9% of cases, respectively. EGFR was
almost exclusively detected in the stromal component of adeno-
sarcoma: 31% of LG adenosarcoma and 75% of HG adenosar-
coma expressed EGFR. Remarkably, ERBB2 was mainly expressed
in the epithelial component of adenosarcoma: 58% of LG ade-
nosarcoma and 100% of HG adenosarcoma showed ERBB2
expression. Although this component is considered benign, it
showed more frequent ERBB2 expression compared with normal
endometrial epithelial cells (P ¼ 0.001 for LG and P < 0.001 for
HG, as determined by c2 test).
Taken together, our data show that PDGFR-a is a potential
target in all uterine sarcoma subtypes, PI3K/mTOR targeting is an
option in 26% of cases, mainly leiomyosarcoma, HGESS and
UUS, and ERBB2/EGFR seem to be targetable in a minority of
cases, mostly adenosarcoma. Recently, pazopanib, a multikinase
inhibitor also targeting PDGFR, was approved for treatment of
leiomyosarcoma after a successful randomized phase III trial (the
PALETTE study; ref. 17), conﬁrming the potential predictive value
of such a histologic scoring system.
In addition, we assessed cyclin D1 expression and the presence
of the t(10;17)(q22;p13) rearrangement, leading to the fusion
gene YMHAE/NUTM2A/B, in HGESS and UUS cases because
these alterations have been linked to HGESS and as the 14-3-3
oncoprotein, resulting from the translocation, has been suggested
Dual PI3K/mTOR Inhibition in Uterine Sarcoma
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as a therapeutic target (18–20). We conﬁrmed that cyclin D1 was
expressedmore in HGESS (7/15; 47%) than in UUS (4/25; 16%),
as shown by the c2 test (P ¼ 0.035). Likewise, previous studies
have reported 8 of 14 and 7 of 18 cyclin D1–positive HGESS
cases (18, 21). Of 12 interpretable HGESS and 19 UUS cases,
only 2 HGESS cases showed the t(10;17) translocation (one
was conﬁrmed by RT-PCR; the other case had no available RNA)
and both had very strong (>90% positive nuclei) cyclin D1
staining, conﬁrming the ﬁndings by Lee and colleagues (ref. 22;
see Supplementary Methods and Supplementary Fig. S3). Our
results are in line with previous studies that detected the translo-
cation with FISH, where 4 of 14 and 4 of 16 cases were positive
(18, 21). Although the portion of translocation-positive cases is
higher in other studies (7/12 and 5/8), this may be explained by
variability between methods, as exempliﬁed by Micci and collea-
gues (20, 23). Cyclin D1 expression did not correlate with DSS,
PFS, or any of the ﬁve investigated proteins.
P-S6S240 expression correlates with recurrent and HG tumors
and with shorter PFS
To identify links between protein expression and tumor char-
acteristics, we checked for correlations with tumor grade and
primary versus recurrent tumors. Remarkably, p-S6S240 was
observed more frequently in HG tumors (66/205; 32%) than in
LG tumors (7/79; 9%; P ¼ 0.004) and was also detected more
frequently in recurrent tumors (15/36; 42%) than in primary
tumors (60/261; 23%; P ¼ 0.016), as calculated by c2 test. Also,
ERBB2 was expressed more frequently in recurrent tumors (5/37;
14%) than in primary tumors (9/264; 3%; P ¼ 0.006). Subse-
quently, logistic regression analyses (correcting for other factors
correlated with grade and recurrence) showed that p-S6S240 was
independently associated with both histologic aggressiveness
(P¼ 0.001; Table 2) and recurrence (P¼ 0.019; Table 3), whereas
ERBB2was associated onlywith recurrence (P¼ 0.011). Together,
these ﬁndings suggest that mTOR pathway activation may be
associated with disease progression in uterine sarcomas. Because
leiomyosarcomas represent the largest uterine sarcoma subgroup,
and are generally HG, we further focused our analyses on this
subgroup. In leiomyosarcoma, phosphorylation of S6S240 was
detected in 29%of cases, signiﬁcantlymore frequently than in LM
(P < 0.001; c2 test) and healthy myometrium (P ¼ 0.018).
P-S6S240 was the only variable that was more often detected in
recurrent leiomyosarcoma (11/22; 50%) than in primary leio-
myosarcoma (32/131; 24%; P ¼ 0.014; c2 test); hence, multivar-
iate analysis was irrelevant. Of note, two primary metastatic
leiomyosarcomas were included in the analysis and both showed
p-S6S240 positivity. To assess the potential prognostic value of the
investigated proteins, we carried out survival analyses in uterine
sarcoma subgroups. Interestingly, p-S6S240 positivity correlated
with shorter PFS in leiomyosarcoma patients (P ¼ 0.034) and
showed a trend toward shorter DSS in univariate analysis (Fig. 1A
and B). Loss of PTEN, which negatively regulates PI3K signaling,
correlated with shorter DSS (P ¼ 0.039) in leiomyosarcoma
patients, but not with PFS (Fig. 1C and D). Multivariate analysis
was not feasible due to the small sample size obtained after
ﬁltering out cases with missing data.
Taken together, our data suggest that p-S6S240 correlates with
HG and recurrent uterine sarcomas, an observation that was also
conﬁrmed in leiomyosarcoma cases, the largest uterine sarcoma
subgroup. In addition, p-S6S240 and PTEN may have prognostic
value in leiomyosarcoma patients.
Dual inhibition of mTOR and PI3K reduces tumor growth
in p-S6S240–positive leiomyosarcoma PDX models
The ﬁnding that p-S6S240 positivity is correlated with HG and
recurrent uterine sarcomas suggests that mTOR pathway activa-
tion may play a central role in uterine sarcoma progression. To
validate this observation, we decided to test the efﬁcacy of mTOR
pathway inhibition in clinically relevant PDX models of uterine
leiomyosarcoma. Despite previous clinical trials with mTOR-
targeting agents for treatment of leiomyosarcoma patients, so far,
noneof the tested compounds (e.g., ridaforolimus, temsirolimus)
have been approved for leiomyosarcoma by the FDA (7). It has
been suggested that the lack of clinical effect could be due to the
feedback activation of AKT as a consequence of mTOR complex 1
(mTORC1) inhibition, which can sustain tumor growth through
mTOR complex 2 (mTORC2) signaling (24, 25). For this reason,
we selected a dual PI3K/mTOR inhibitor, BEZ235, also able to
block mTORC2. Five PDX models were derived from uterine
leiomyosarcoma of different patients, from which the clinical
Table 2. Logistic regression: predictors of HG versus LG histology
Variable N Univariate OR (95% CI) P Multivariate OR (95% CI) P
p-S6S240
Negative 120 1
Positive 44 5.385 (1.803–16.082) 0.003 7.242 (2.294–22.866) 0.001
Tumor size 164 1.176 (1.076–1.286) <0.001 1.158 (1.056–1.270) 0.002
Age 164 1.034 (1.008–1.061) 0.010 1.027 (0.998–1.057) 0.064
NOTE: Logistic regression with "LG histology" as a reference. OR > 1 and P < 0.05 indicate a statistically signiﬁcant correlation of the variable with HG histology.
P-values in bold indicate a signiﬁcant effect in multivariate analysis.
Abbreviations: CI, conﬁdence interval; OR, odds ratio.
Table 3. Logistic regression: predictors of recurrent versus primary tumor samples
Variable N Univariate OR (95% CI) P Multivariate OR (95% CI) P
p-S6S240
Negative 222 1
Positive 75 2.393 (1.162–4.929) 0.018 2.408 (1.156–5.016) 0.019
ERBB2
Negative 283 1
Positive 14 4.516 (1.423–14.336) 0.011 4.567 (1.406–14.827) 0.011
NOTE: Logistic regression with "primary tumors" as a reference. OR > 1 and P < 0.05 indicate a statistically signiﬁcant correlation of the variable with recurrent
samples. P-values in bold indicate a signiﬁcant effect in multivariate analysis.
Abbreviations: CI, conﬁdence interval; OR, odds ratio.
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characteristics are shown in Supplementary Table S4. Eachmodel
was treated for 3 weeks with BEZ235, placebo, and trabectedin
(Yondelis), an alkylating chemotherapeutic agent approved for
leiomyosarcoma treatment after failure of anthracyclines. We
chose trabectedin as a chemotherapy control as it is the youngest,
most recently approved chemotherapy. Its antiproliferative prop-
erties rely on multiple mechanisms, including the inhibition of
transactivated transcription and the interaction with DNA repair
proteins (26). Of ﬁve treated leiomyosarcoma models, four
showed response to dual PI3K/mTOR inhibition (Fig. 2).Whereas
the tumor volume was stabilized in EMC029, tumor growth was
slowed down in EMC050. Furthermore, tumor shrinkage was
observed in EMC036 (21% reduction, compared with placebo)
and EMC041 (35% reduction, compared with placebo). No
response to BEZ235was noted in EMC031, a recurrent, pretreated
leiomyosarcoma. Response to trabectedin was noted in four
models, while EMC029 showed a trend (nonsigniﬁcant) toward
response after 8 days. No mice in any arms of the treatment
experiments showed signiﬁcant weight loss (data not shown).
Interestingly, the four responding models showed in their
placebo-treated tumors expression of p-S6S240, with mean scores
between 6.3 and 7.8 (see Table 4 for mean scores; representative
images are shown in Fig. 2), whereas all BEZ235-treated tumors
were scored as negative. In the nonresponding model (EMC031),
p-S6S240 staining in placebo-treated tumors was scored as nega-
tive, with amean score of 5.1. These ﬁndings suggest that p-S6S240
expression can be used to predict response to PI3K/mTOR block-
age in leiomyosarcoma.
To extend our testing of dual PI3K/mTOR inhibition beyond
BEZ235, EMC041 was additionally treated with a combination of
themTORC1/2 inhibitor TAK-228, also known as sapanisertib, and
the PI3Ka inhibitor alpelisib. The combination of TAK-228 and
alpelisib was as effective as BEZ235 in inhibiting tumor growth (no
signiﬁcant difference between both treatment groups), supporting
Figure 1.
Survival of leiomyosarcoma patients according to p-S6S240 and PTEN expression. A–D, Kaplan–Meier survival curves showing DSS (A and C) and PFS (B and D)
of leiomyosarcoma patients. A and B, The log-rank test with corresponding P values applies to the p-S6S240–negative (red) and p-S6S240–positive (green)
curves. Blue curves (all leiomyosarcomas) are depicted as comparison. The number of patients in the analyses is indicated next to the curve with number of
events between brackets. C and D, The log-rank test applies to the PTEN-negative (red) and PTEN-positive (green) curves.
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Figure 2.
In vivo dual inhibition of mTOR and PI3K by BEZ235 in uterine leiomyosarcoma PDX models. Mice were treated with BEZ235, trabectedin (as a chemotherapy
control), or placebo. Tumor volumes were measured twice weekly, and growth curves of treated mice were compared with placebo-treated mice using
two-way repeated measures ANOVA. Data points and error bars represent mean values and SEM. Signiﬁcant effects (compared with placebo) are indicated with
 and  . Tumor growth curves are depicted with p-S6S240 stainings and scores of representative tumors of each model (left, placebo-treated tumor; right,
BEZ235-treated tumor). Pictureswere taken at20magniﬁcation (scale bar, 50mm)andat40magniﬁcation for EMC029 (scale bar, 20mm). A largermagniﬁcation
was used for EMC029 to increase visibility as the cells show a small amount of cytoplasm. Numbers of mice for placebo, trabectedin, and BEZ235-treated
groups are respectively: EMC036: n ¼ 6, 6, 5; EMC050: n ¼ 6, 7, 6; EMC041: n ¼ 6, 3, 6; EMC029: n ¼ 5, 4, 5; EMC031: n ¼ 7, 7, 9.
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in general our approach of dual PI3K/mTOR inhibition in leio-
myosarcoma (Supplementary Methods; Supplementary Fig. S4).
Thus, four of ﬁve uterine leiomyosarcoma models, which were
p-S6S240 positive, responded to dual PI3K/mTOR inhibition,
which can represent anew therapeutic option for leiomyosarcoma
patients with p-S6S240–positive tumors.
Discussion
We analyzed a large cohort of samples from uterine sarcoma
patients for the expression of selected druggable therapeutic
targets, to determine the subgroups for which speciﬁc targeted
agents would be the most potentially effective.
Here, we show that PDGFR-a is expressed in the majority of
samples, in all sarcoma subtypes. Importantly, after initiation of
this study, pazopanib, targeting PDGFR, KIT, FGFR, and VEGFR,
was approved for the treatment of leiomyosarcomapatients after a
successful placebo-controlled phase III trial (17). Another recent
phase II trial showed the addition of PDGFR-a inhibitor olar-
atumab todoxorubicin is beneﬁcial in soft tissue sarcomapatients
(including leiomyosarcoma; ref. 27). Our results conﬁrm that
PDGFR-a is frequently expressed in uterine leiomyosarcoma, but
also other uterine sarcoma types show expression in at least 75%
of cases, suggesting that pazopanib/olaratumab should also be
tested in other uterine sarcoma subtypes. Of note, 2 LGESS
patients have been reported to show response to imatinib in case
reports, encouraging further studies (28, 29). Although one case
expressed KIT (PDGFR status unknown), the other case showed
no KIT expression or activating mutation, but was strongly pos-
itive for PDGFR, suggesting imatinib acted through PDGFR in the
latter case. Indeed, because KIT is notmutated in uterine sarcomas
(6), imatinib may exert its effect by PDGFR blocking in uterine
sarcomas (9).
ERBB2 and EGFR, although being important targets in other
cancer types, havenot been studied frequently in uterine sarcomas
(7). An exception is the study by Movva and colleagues (6),
describing that ERBB2 is rarely overexpressed in leiomyosarcoma
and ESS. In our sample set, ERBB2 and EGFRwere rarely detected,
except in adenosarcoma. ERBB2 was expressed in the epithelial
component in 58% of LG adenosarcoma and in 100% of HG
adenosarcoma cases. Contrarily, EGFR expression in adenosar-
coma was seen in a minority of epithelial cells, whereas it was
expressed in the stromal component in 31% of LG adenosarcoma
and in 75% of HG adenosarcoma cases. This stromal–epithelial
distribution of EGFR and ERBB2 in adenosarcoma is in line with
their expression pattern in carcinosarcomas (30–32). Only two
other studies reported on the expression of EGFR (2/6 positive
cases) and ERBB2 (0/6 and 0/10 positive cases) in adenosarcoma,
but without evaluating the epithelial component (30, 32). In
addition, we show that in uterine sarcomas, ERBB2 is more
frequently detected in recurrent samples than in primary tumors,
suggesting that ERBB2 may play a role in sarcoma progression.
The PI3K/mTOR pathway has been implicated in the patho-
genesis of leiomyosarcoma, and preclinical studies have shown
effect of mTOR-targeting agents (7, 8). A negative regulator of
PI3K/mTOR signaling, PTEN, is frequently deleted in leiomyo-
sarcoma (6, 33). In our cohort, absence or low expression of PTEN
was noted in 28%of leiomyosarcoma samples. This is concordant
with earlier ﬁndings, showing decreased expression of PTEN in
20% to 38% of leiomyosarcoma cases (6, 34). Another study
reported PTEN loss by IHC in only 7%of uterine leiomyosarcoma
(35). This discrepancy is likely due to the use of different
scoring systems. In leiomyosarcoma patients, we showed that
PTEN loss correlates with shorter DSS. PTEN loss has been
shown previously to have prognostic value in other gynecologic
cancer types (36, 37). Next to its prognostic role, loss of PTEN
may also guide therapy decisions. Indeed, PTEN-deﬁcient
tumors may be more sensitive to PARP inhibitors, due to
PTEN's role in genomic integrity, with PTEN loss leading to
defects in homologous recombination (38).
Downstream tomTOR signaling, S6 kinases (S6K) are activated
through phosphorylation. A well-known target of S6K is the S6
ribosomal protein, a component of the 40S ribosomal protein.
Here, we used the phosphorylated formof S6 as a read-out for S6K
activity, and thus mTOR pathway activation (39). The S6 protein
can be phosphorylated at serines 235/236 and 240/244. Pende
and colleagues (40) have described phosphorylation at S235/236
even when mTOR-activated kinases S6K1 and 2 are knocked out.
In this situation, phosphorylation at S240/244 was obliterated,
suggesting that mTOR-activated S6K1/2s are the only kinases
responsible for phosphorylation at serines 240/244 in the S6
protein (40). Therefore, we chose to detect S6 phosphorylation at
serine 240 using a phospho-site–speciﬁc antibody. In our dataset,
29% of uterine leiomyosarcoma samples showed p-S6S240 pos-
itivity, signiﬁcantly more than in benign lesions and normal
tissue. Similarly, Brewer Savannah and colleagues (35) reported
24% of uterine leiomyosarcoma to be strongly positive, and
Hernando and colleagues (41) found 44% of soft tissue leiomyo-
sarcoma samples to be p-S6S240 positive. Setsu and colleagues
(34) found 74,5% of soft tissue leiomyosarcoma samples to be
p-S6S235/236 positive. However, the latter report did not include
uterine lesions and used a lower cutoff for positivity.
In our study, p-S6S240 staining was observed more in HG and
recurrent tumors, suggesting that S6 phosphorylationmight be an
event linked to disease progression. This ﬁnding is in line with the
previous report of Brewer Savannah and colleagues (35), who
observed higher levels of p-S6S235/236 in recurrent and metastatic
uterine leiomyosarcoma lesions. We are the ﬁrst to report this
ﬁnding in a large cohort of 153 uterine leiomyosarcoma patients.
Furthermore, we show that p-S6S240 positivity correlates with
Table 4. Response of PDX models to BEZ235 with p-S6S240 scores
Model Response to BEZ235
p-S6S240 mean score
placebo-treated tumors
p-S6S240 status placebo-
treated tumors
EMC036 Decrease in tumor volume 7.8 Positive
EMC050 Decrease in tumor growth 7.7 Positive
EMC041 Decrease in tumor volume 7.0 Positive
EMC029 Stable tumor volume 6.3 Positive
EMC031 No response 5.1 Negative
NOTE: Five PDX models were treated with BEZ235, trabectedin, and placebo. Placebo-treated tumors were scored for p-S6S240 level. For each model, the mean
scores of all placebo-treated tumors are depicted.
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shorter PFS in leiomyosarcoma patients; hence, p-S6S240 could be
a prognostic marker in leiomyosarcoma patients.
MTOR inhibition showed modest effectiveness in preclinical
studies and in clinical trials on sarcomas, where leiomyosarcoma
patients (origin not speciﬁed) showed minor response to ridafor-
olimus and temsirolimus (7, 42, 43). Taking into account their
limited clinical effect, as well as the toxicities, the FDA has not
approved mTOR inhibitors for leiomyosarcoma patients so far.
This limited efﬁcacy may be partly due to the absence of patient
selection, as no predictive markers are currently available. In
addition, these compounds only inhibit mTORC1, which may
lead to feedback activation of AKT and sustained signaling
through mTORC2 (25). New-generation inhibitors targeting also
mTORC2, as well as PI3K, have not been tested in gynecologic
sarcomas until very recently. SK-LMS-1, a vulvar leiomyosarcoma
cell line, has proven to be sensitive to BEZ235, the same dual
PI3K/mTOR inhibitor that we tested in our study (44). BEZ235
has also been shown to inhibit the proliferation of pazopanib-
resistant retroperitoneal undifferentiated pleomorphic sarcoma
(UPS) cells (45). However, in a genetically engineered mouse
model ofUPS, BEZ235 inhibited tumor growth inonly 3of 9mice
(46). BEZ235 inhibits various sarcoma cell lines, including rhab-
domyosarcoma, Ewing sarcoma, osteosarcoma, and chondrosar-
coma cells in vitro, although reported in vivomodels show varying
response (47, 48).
In contrast with the cell line–based in vivo models, which
have been used in most studies on sarcomas, we have chosen to
establish PDX models, which better represent the original
tumor characteristics (13). Here, we show a strong response
of uterine leiomyosarcoma PDX models to BEZ235. Unfortu-
nately, after initiation of this study, BEZ235 development was
discontinued by Novartis, mainly due to toxicity (49).
BEZ2350s clinical toxicity proﬁle was unexpected because no
such adverse effects were observed in our preclinical tests or in
previous preclinical studies (47, 48). However, our results
provide preclinical evidence for the efﬁcacy of dual PI3K/mTOR
inhibition in uterine leiomyosarcoma patients, supporting the
use of other (less toxic) dual PI3K/mTOR inhibitors like geda-
tolisib (Pﬁzer), as well as combinations of PI3K inhibitors (e.g.,
alpelisib by Novartis) and mTOR inhibitors (e.g., TAK-228 by
Takeda). Indeed, we here show that combined administration
of mTORC1/2 inhibitor TAK-228 and PI3Ka inhibitor alpelisib
results in an equal tumor inhibition as obtained by BEZ235,
supporting our approach of dual PI3K/mTOR targeting in
leiomyosarcoma. Intriguingly, models showing p-S6S240
expression responded better to PI3K/mTOR targeting, suggest-
ing that p-S6S240 could be used as a predictive marker for
response to PI3K/mTOR–directed agents. Iwenofu and collea-
gues (50) have previously suggested a role for p-S6S235/236 in
response prediction to ridaforolimus in sarcoma patients;
however, no uterine sarcomas were included in their study
(50). Taken together, our ﬁndings suggest that dual PI3K/
mTOR targeting might be an effective strategy in uterine
leiomyosarcoma.
In conclusion, the expression of ﬁve therapeutically relevant
proteins was assessed in all uterine sarcoma subtypes, as well as in
benign uterine tumors and normal tissues. In a set of 303 uterine
sarcomas, we show that p-S6S240 expression identiﬁes sarcomas
with a poor prognosis and predicts response to dual PI3K/mTOR
inhibition in PDX leiomyosarcoma models.
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